A. Haydon

S. Loi, A. Haydon, P. Bergin, 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy

E. Blackley, A. Haydon, P. Bergin, 2017, British Journal of Cancer.

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases

R. Kefford, G. McArthur, G. Long, 2016, British Journal of Cancer.

Yield of baseline imaging for distant metastases in high‐risk primary melanoma

M. Shackleton, A. Haydon, V. Mar, 2022, Journal of surgical oncology.

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.

B. Vogelstein, P. Gibbs, L. Lipton, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Stereotactic radiotherapy combined with immunotherapy against metastatic melanoma: Long term results of a phase I clinical trial.

M. V. van Zelm, M. Shackleton, J. Ruben, 2020, International journal of radiation oncology, biology, physics.

Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.

T. John, M. Shackleton, B. Markman, 2020, Clinical lung cancer.

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

S. Haferkamp, R. Dummer, J. Kirkwood, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma.

R. Sullivan, P. Ascierto, J. McQuade, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Salvage treatment using anti-PD-1/CTLA-4 immunotherapy after failure of neoadjuvant chemotherapy in microsatellite instable gastroesophageal carcinoma.

A. Haydon, O. Klein, W. Brown, 2021, The oncologist.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

D. Schadendorf, S. Puig, P. Ascierto, 2021, The Lancet. Oncology.

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D. Schadendorf, P. Ascierto, A. Bottomley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?

M. Stockler, D. Goldstein, M. Jefford, 2018 .

Updated results of the SCOT study : An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer

J. Tabernero, B. Glimelius, A. Haydon, 2017 .

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy.

R. Dummer, S. Patel, C. Blank, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.

R. Sullivan, Douglas B. Johnson, I. Osman, 2021, JAMA oncology.

Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.

K. Stangl, Joshua Levenson, K. Aonuma, 2022, European journal of cancer.

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

D. Schadendorf, S. Puig, P. Ascierto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

A. Hauschild, D. Schadendorf, R. Dummer, 2020, The New England journal of medicine.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2019, European journal of cancer.

High neutrophil‐to‐lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy

A. Haydon, S. Davis, Sahan Chandrasekara, 2018, Asia-Pacific journal of clinical oncology.

18F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy

A. Haydon, M. Cherk, K. Yap, 2022, Journal of medical imaging and radiation oncology.

Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID‐19 pandemic

G. McArthur, A. Haydon, S. McLachlan, 2020, Internal medicine journal.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

M. Weichenthal, K. Kähler, P. Ascierto, 2022, Journal for ImmunoTherapy of Cancer.

Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study

R. Wolfe, S. Zoungas, M. Shackleton, 2022, Cardio-Oncology.

Poster Presentations

R. Wolfe, C. McLean, A. Haydon, 2018 .

Metastatic pathways in patients with cutaneous melanoma

A. Haydon, J. Kelly, V. Mar, 2017, Pigment cell & melanoma research.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2017, The New England journal of medicine.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

S. Dawson, M. Dawson, N. Dhomen, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

D. Schadendorf, S. Puig, P. Ascierto, 2020, JAMA oncology.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

D. Schadendorf, S. Puig, P. Ascierto, 2018, The New England journal of medicine.

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

A. Briggs, T. Hickish, J. Tabernero, 2018, The Lancet. Oncology.

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy

G. McArthur, R. Wolfe, A. Haydon, 2018, British Journal of Cancer.

Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.

M. Ranson, P. Hersey, G. Margison, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres.

A. Polglase, S. Skinner, Y. Antill, 2018, International journal of surgery.

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

M. Sawyer, D. Tu, M. Moore, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.

R. Strausberg, K. Kinzler, B. Vogelstein, 2016 .

Concordance of somatic mutational profile in multiple primary melanomas

G. McArthur, R. Wolfe, A. Haydon, 2018, Pigment cell & melanoma research.

Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics

S. Luen, G. McArthur, A. Haydon, 2015, American journal of clinical oncology.

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation‐positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists

M. Millward, R. Kefford, G. McArthur, 2016, Asia-Pacific journal of clinical oncology.

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

J. Sosman, M. Lacouture, Douglas B. Johnson, 2021, Journal for ImmunoTherapy of Cancer.

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.

Douglas B. Johnson, G. Long, O. Michielin, 2021, European journal of cancer.

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

P. Ascierto, Douglas B. Johnson, C. Blank, 2021, The Lancet. Oncology.

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

Douglas B. Johnson, P. Ott, G. Long, 2021, Journal for ImmunoTherapy of Cancer.

Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma

M. Millward, G. Long, S. Lo, 2020, Pigment cell & melanoma research.

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

A. Haydon, C. Mueller, V. Atkinson, 2020, Journal for ImmunoTherapy of Cancer.

1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]

G. Daniels, D. Rischin, A. Haydon, 2021, Annals of Oncology.

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

J. Desai, B. Solomon, M. Brown, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An update on adjuvant systemic therapies in melanoma

M. Shackleton, A. Haydon, M. Moore, 2019, Melanoma management.

Tumour mutation status and sites of metastasis in patients with cutaneous melanoma

G. McArthur, R. Wolfe, A. Haydon, 2017, British Journal of Cancer.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

A. Hauschild, A. Testori, M. Del Vecchio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

D. Schadendorf, S. Puig, P. Ascierto, 2021, The Lancet. Oncology.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2019, The Lancet. Oncology.

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

A. Hauschild, D. Schadendorf, R. Sullivan, 2020, British Journal of Cancer.

Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises

A. Haydon, P. Bhave, 2020, The Australasian journal of dermatology.

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.

S. Puig, P. Ascierto, A. Eggermont, 2020 .

Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, S. Puig, P. Ascierto, 2022, European journal of cancer.

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2021, Clinical Trials.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

S. Dawson, M. Dawson, N. Dhomen, 2019 .

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic melanoma presenting as intravenous tumour thrombus

M. Shackleton, A. Haydon, M. Moore, 2020, Journal of medical imaging and radiation oncology.

Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies

J. Ptak, K. Kinzler, B. Vogelstein, 2020, International journal of cancer.

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial.

A. Hauschild, D. Schadendorf, R. Dummer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA46 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial

P. Ascierto, A. Eggermont, M. Mandalà, 2020 .

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma

J. Zalcberg, M. Millward, R. Gonzalez, 2008, Investigational New Drugs.

Caution in the age of optimism; a salient lesson in advanced melanoma

A. Haydon, H. Roberts, 2020, Annals of translational medicine.

The Victorian Melanoma Service: A 20‐year review of an Australian multidisciplinary cancer service

A. Haydon, C. Mclean, J. Kelly, 2016, Australasian Journal of Dermatology.

The role of surveillance imaging for resected high‐risk melanoma

M. Shackleton, R. Wolfe, A. Haydon, 2022, Asia-Pacific journal of clinical oncology.

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.

P. Ascierto, Douglas B. Johnson, G. Long, 2021, The Lancet. Oncology.

Prognosis associated with cutaneous melanoma metastases

A. Haydon, C. Mclean, J. Kelly, 2015, The Australasian journal of dermatology.

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

A. Briggs, T. Hickish, J. Tabernero, 2019, Health technology assessment.

Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer.

J. Tabernero, B. Glimelius, A. Haydon, 2017 .

Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.

A. Briggs, J. Tabernero, B. Glimelius, 2015 .

1242PNeutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma

E. Blackley, A. Haydon, M. Moore, 2017 .

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

D. Schadendorf, P. Ascierto, A. Eggermont, 2022, NEJM evidence.

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

D. Schadendorf, P. Ascierto, C. Blank, 2023, European journal of cancer.

Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors

J. Desai, B. Solomon, M. Brown, 2016 .

Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.

A. Haydon, C. Mueller, V. Atkinson, 2018 .

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

N. Pavlakis, D. Goldstein, N. Waterhouse, 2023, Journal for ImmunoTherapy of Cancer.

Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma.

G. Long, C. Robert, C. Lebbé, 2022, European journal of cancer.

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

K. Kähler, Douglas B. Johnson, G. McArthur, 2023, Journal for ImmunoTherapy of Cancer.

Long Survival (Cure) to Cisplatin/Infusional 5-Flurouracil in Metastatic Squamous Cell Anal Cancer with Extensive Liver and Lung Metastases

J. Shapiro, A. Haydon, G. Mak, 2015 .

Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995–2009

A. Haydon, S. Roberts, W. Kemp, 2013, Internal medicine journal.

Reduced melanoma referrals during COVID-19 lockdown.

M. Shackleton, A. Haydon, V. Mar, 2021, Australian journal of general practice.

Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy.

M. V. van Zelm, A. Haydon, N. Wong, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation

J. Desai, N. Pavlakis, L. Chantrill, 2015 .

Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot

J. Zalcberg, A. Haydon, A. Maciejewska, 2022, ANZ journal of surgery.

Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.

Douglas B. Johnson, I. Osman, G. Long, 2023, Journal of Clinical Oncology.

Management of resected stage III/IV melanoma with adjuvant immunotherapy.

G. Long, A. Menzies, M. Carlino, 2021 .

Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.

S. Puig, P. Ascierto, A. Eggermont, 2019, Journal of Clinical Oncology.

Towards evidence‐based use of serum tumour marker requests: an audit of use in a tertiary hospital

S. Loi, A. Haydon, A. Haydon, 2004, Internal medicine journal.

Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).

Douglas B. Johnson, P. Ott, G. Long, 2020 .

Prognosis associated with cutaneous melanoma metastases

A. Haydon, J. Kelly, Yan Pan, 2015, The Australasian journal of dermatology.

Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma in Patients with Concomitant Chronic Lymphocytic Leukemia.

J. McQuade, J. Wargo, E. Keung, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

G. Long, M. Carlino, A. Haydon, 2017 .

Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.

M. Sawyer, D. Tu, M. Moore, 2012 .

Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma

Douglas B. Johnson, I. Osman, G. Long, 2023, JAMA network open.